Chronic Inflammatory Demyelinating Polyneuropathy

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a neurological disorder characterized by progressive weakness and impaired sensory function in the arms and legs.

Featured Video

European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second Revision

CIDP

Watch Dr. Peter Van den Bergh, lead author, take you through the highlights of the guideline.

Videos about CIDP

VIEW ALL VIDEOS

IgG Levels and Wear Off Reflect Administration and Outcome

Carol L. Koski, MD

GBS/CIDP Foundation International

5:51 MIN

CIDP
GBS

Learn more about how IgG levels and their wear off reflect treatment administration and outcomes in individual IVIG- or SCIG-treated patients with immunodeficiency and peripheral inflammatory neuropathy disorders.

DOWNLOAD PDF

Clinical Studies for the Treatment of CIDP with Immunoglobulin

Claudia Sommer, MD

University of Würzburg, Würzburg, Germany

9:35 MIN

CIDP

Learn about clinical studies for the treatment of CIDP with immunoglobulin.

DOWNLOAD PDF

Pathogenesis and Mechanism of Action of Inflammatory Neuropathies

Richard A. Lewis, MD

Cedars-Sinai Medical Center, Los Angeles, CA, USA

13:53 MIN

CIDP
GBS
MMN

Find out what pathogenic processes are involved in acute and chronic inflammatory neuropathies, including GBS, CIDP, and MMN.

DOWNLOAD PDF

20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (PATH): a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial

Vera Bril, BSc, FRCPC, MD

University of Toronto,Toronto, Canada

15:31 MIN

CIDP

Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP

DOWNLOAD PDF

NOW PLAYING

5:51

IgG Levels and Wear Off Reflect Administration and Outcome

NOW PLAYING

9:35

Clinical Studies for the Treatment of CIDP with Immunoglobulin

Learn about clinical studies for the treatment of CIDP with immunoglobulin.

NOW PLAYING

13:53

Pathogenesis and Mechanism of Action of Inflammatory Neuropathies

Find out what pathogenic processes are involved in acute and chronic inflammatory neuropathies, including GBS, CIDP, and MMN.

NOW PLAYING

15:31

20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Poly...

Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP

Our Experts on CIDP

VIEW ALL EXPERTS

Mel Berger, MD, PhD

Medical Research Strategy, CSL Behring

Mel Berger, MD, PhD

Medical Research Strategy, CSL Behring

CIDP

Mel Berger is a Senior Director, Medical Research Strategy at CSL and Adjunct Professor of Pediatrics and Pathology, Case Western Reserve University. He earned his undergraduate, medical and PhD (in Biochemistry) degrees at Case Western Reserve University in Cleveland.

Karissa Gable, MD

Duke University Medical Center in Durham, North Carolina

Karissa Gable, MD

Duke University Medical Center in Durham, North Carolina

CIDP

Dr. Karissa Gable is a Neuromuscular specialist at Duke University Medical Center in Durham, North Carolina.

Peter Donofrio, MD

Vanderbilt University Medical Center, Nashville, TN, USA

Peter Donofrio, MD

Vanderbilt University Medical Center, Nashville, TN, USA

CIDP
GBS

Peter D. Donofrio, M.D. is a Professor of Neurology at Vanderbilt University Medical Center. He is a graduate of The Ohio State University School of Medicine and pursued a residency in neurology and a neuromuscular fellowship at the University of Michigan.

Jeffrey A. Allen, MD

University of Minnesota